With the sale of the Doliprane manufacturer Orpella, André Chassaigne denounces “the chronicle of a planned industrial death” and makes the link with the uncertain future of the Euroapi factory in Vertolaye (Puy-de-Dôme), sold by Sanofi in 2022.
Audrey Duval, president of Sanofi France, was heard on October 24 by the Economic Affairs Committee of the National Assembly on the sale of Orpella, manufacturer of Doliprane, to an American investment fund.
The future of the EuroApi pharmaceutical site in Vertolaye worries
Opposed to this decision, the Puydômois communist deputy André Chassaigne denounced “the chronicle of a planned industrial death” and made the link with the uncertain future of the Euroapi group, owner of a factory in Vertolaye bought from Sanofi in 2022.
Sanofi’s commitments
In response, Sanofi managers confirmed a double commitment: to participate to the tune of 200 million euros in the investment plan announced last June by the Euroapi group and to maintain its participation in the capital, currently 30%, until December 2025.
France
